Menu Close
  • Clinical
    • In the Literature
    • Key Clinical Questions
    • Interpreting Diagnostic Tests
    • Coding Corner
    • Clinical
    • Clinical Guidelines
    • COVID-19
    • POCUS
  • Practice Management
    • Quality
    • Public Policy
    • How We Did It
    • Key Operational Question
    • Technology
    • Practice Management
  • Diversity
  • Career
    • Leadership
    • Education
    • Movers and Shakers
    • Career
    • Learning Portal
    • The Hospital Leader Blog
  • Pediatrics
  • HM Voices
    • Commentary
    • In Your Eyes
    • In Your Words
  • SHM Resources
    • Society of Hospital Medicine
    • Journal of Hospital Medicine
    • SHM Career Center
    • SHM Converge
    • Join SHM
    • Converge Coverage
    • SIG Spotlight
    • Chapter Spotlight
    • #JHM Chat
  • Industry Content
    • Patient Monitoring with Tech
An Official Publication of
  • Clinical
    • In the Literature
    • Key Clinical Questions
    • Interpreting Diagnostic Tests
    • Coding Corner
    • Clinical
    • Clinical Guidelines
    • COVID-19
    • POCUS
  • Practice Management
    • Quality
    • Public Policy
    • How We Did It
    • Key Operational Question
    • Technology
    • Practice Management
  • Diversity
  • Career
    • Leadership
    • Education
    • Movers and Shakers
    • Career
    • Learning Portal
    • The Hospital Leader Blog
  • Pediatrics
  • HM Voices
    • Commentary
    • In Your Eyes
    • In Your Words
  • SHM Resources
    • Society of Hospital Medicine
    • Journal of Hospital Medicine
    • SHM Career Center
    • SHM Converge
    • Join SHM
    • Converge Coverage
    • SIG Spotlight
    • Chapter Spotlight
    • #JHM Chat
  • Industry Content
    • Patient Monitoring with Tech

Cardiology

  • 1
    News

    Suboptimal statin response predicts future risk

    June 29, 2020

    What are the differences in LDL cholesterol responses among primary prevention patients prescribed statins, and do those differences predict future cardiovascular risk?

  • 1
    News

    How to reboot elective CV procedures after COVID-19 lockdown

    June 26, 2020

    Top cardiology societies provide strategies and considerations for ramping up elective CV imaging, electrophysiology, and remote arrhythmia monitoring as restrictions ease.

  • 1
    News

    COVID-19: ‘dramatic’ surge in out-of-hospital cardiac arrests in NYC

    June 26, 2020

    At the height of the COVID-19 pandemic in New York City, first responders faced nearly triple the number of calls for cardiac arrest compared with the same period a year earlier.

  • 1
    News

    Dapagliflozin benefits low-EF heart failure regardless of diuretic dose: DAPA-HF

    June 26, 2020

    The trial that turned an SGLT2 inhibitor into a heart failure drug also has clues to mechanisms behind the observed benefits. Contrary to early speculation, diuresis may be off the list.

  • 1
    News

    VA readmissions program not linked to increased death

    June 26, 2020

    Unlike CMS’s hospital readmissions program, the VA’s program had no financial penalties. A new analysis shows heart failure readmissions are down and mortality unchanged in the VA setting.

  • 1
    News

    ED visits for life-threatening conditions declined early in COVID-19 pandemic

    June 23, 2020

    Visits for MI, stroke, and hypoglycemic crisis dropped 10%-23% over the first 10 weeks.

  • 1
    News

    Cost of preventable adult hospital stays topped $33 billion in 2017

    June 23, 2020

    Heart failure, diabetes, and COPD were the most expensive preventable conditions.

  • News

    CVD risk continues to fall down to systolic BP of 90 mm HG

    June 19, 2020

    “From an individual level we can now say that in healthy individuals, a systolic pressure in the 90s is not too low. It is a positive thing.”

  • 1
    Opinion

    Preventing arrhythmias and QTc prolongation in COVID-19 patients on psychotropics

    June 18, 2020

    Psychotropics associated with QTc interval prolongation should be discontinued (or substituted with a low-risk agent) if a patient presents with suspected COVID-19.

  • 1
    News

    DAPA-HF: Dapagliflozin slows T2D onset in heart failure patients

    June 16, 2020

    In the landmark DAPA-HF trial that enrolled HFrEF patients without diabetes, treatment with dapagliflozin cut incident type 2 diabetes by a relative 32%.

Previous1 … 29 30 31 32 33 … 79Next
  • About The Hospitalist
  • Contact Us
  • The Editors
  • Editorial Board
  • Authors
  • Publishing Opportunities
  • Subscribe
  • Advertise
fa-facebookfa-linkedinfa-instagramfa-youtube-playfa-commentfa-envelopefa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies.
    ISSN 1553-085X
  • Privacy Policy
  • Terms and Conditions
  • SHM’s DE&I Statement
  • Cookie Preferences